natgillin/translations-raw huggingface dataset:
Ferritto Crespo et al. 
Ferritto Crespo i dr.
A neutralising antibody which binds human IL-17A and human IL-17F having a light chain wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:7. 
Neutralizirajuće antitijelo koje veže ljudski IL-17A i ljudski IL-17F koji ima laki lanac i teški lanac, naznačeno time da varijabilna domena lakog lanca obuhvaća sekvencu danu u SEQ ID BR:7 i varijabilnu domenu teškog lanca koja sadrži sekvencu danu u SEQ ID BR:9.
For example, as shown in FIG. 13, paclitaxel of Formula 1 (where R1═R2═Ph; R7═CH3 in generalized formula A of Scheme 1) is first protected at the 2′-hydroxyl with a hydroxyl protecting group such as tert-butyldimethylsilyl (TBDMS). 
Na primjer, kao što je prikazano na slici 13, paklitaksel formule 1 (gdje Ri=R>=Ph; R;=CH; u općoj formuli A iz sheme 1) je najprije zaštićen na 2'-hidroksilu s hidroksil zaštitnom skupinom kao što je tert-butildimetilsilil (TBDMS).
The method of claim 29 wherein the disease or disorder is a tumor-related disease. The method of claim 30 wherein the tumor-related disease is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 6 naznačeno time, što bolest ili poremećaj je bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz skupine koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma pankreasa, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave-vrata, karcinoma žučne vrećice i njihovih metastaza.
The solid dosage form of claim 1, wherein said surfactant having an HLB value of from 4 to 10 is a sorbitan fatty acid ester. 
Dozirni oblik prema zahtjevu 3 gdje je farmaceutski prihvatljiv surfaktant sorbitan ester masne kiseline.
the pyrimidine analogue is gemcitabine, 5-FU, or capecitabine; or a pharmaceutically acceptable salt thereof. 
analog pirimidina je gemcitabin, 5-FU ili kapecitabin ili njihova farmaceutski prihvatljiva sol.
In a further of its aspects, the present invention may provide a manual switch apparatus to be worn about the body of a user including: a switch box means having a body with a manually operable switch device for controlling the operation of a remote communications apparatus; a support means having attachment means for attaching the support means about the body of a user, the support means being shaped to releasably receive at least a part of the body of the switch box means thereby to selectively retain the switch box means in either of two different positions in which the orientation of the switch device relative to the support means is substantially reversed as between said two positions. 
Slušalice prema bilo kojem od prethodnih zahtjeva, naznačene time, da obuhvaćaju ručni sklopni aparat koji se nosi oko tijela korisnika, pri čemu ručni sklopni aparat obuhvaća sljedeće: preklopna kutija (510) koja ima osnovu s ručno operabilnim preklopnim uređajem za upravljanje radom daljinskog komunikacijskog aparata; nosivi element (530) koji ima priključni uređaj za pričvršćivanje nosivog elementa oko tijela korisnika, pri čemu je nosivi element oblikovan za oslobađajući prihvat barem dijela od osnove preklopne kutije, čime se preklopna kutija selektivno zadržava u jednom od dva različita položaja u kojima je orijentacija preklopnog uređaja u odnosu na nosivi element bitno obrnuta nego kao što je između navedena dva položaja.
The resulting suspension is filtered and concentrated in vacuo with toluene azeotroping. 
Dobivenu suspenziju se profiltrira i koncentrira u vakuumu azeotropno s toluenom.
mixing about 53 parts of the water phase resulting from step (iv) with about 27 parts butter, and about 17 parts rapeseed oil. 
(v) miješanje 53 dijela vodene faze dobivene u koraku (iv) s 27 dijelova maslaca i 17 dijelova ulja uljane repice.
In certain embodiments, step (b) comprises admixing from about 1% to about 10% of a semicrystalline polymer. 
(b) korak (b) obuhvaća miješanje od oko 1 % do oko 10 % polukristalnog polimera; ili
These mutated and over-expressed forms of the kinase are present in a large proportion of human tumours (reviewed in Kolibaba et al, Biochimica et Biophysica Acta, 1997, 133, F217-F248). 
Ovi mutirani i overeksprimirani oblici kinaze pojavljuju se u velikom udjelu humanih tumora (pregledano u Kolibaba i sur, Biochimica et Biophysica Acta, 1997, 133, F217-F248).
combining said population of lipoprotein complexes with one or more pharmaceutically acceptable excipients. 
miješanje lipoproteinskih kompleksa s jednom ili više farmaceutski prihvatljivih pomoćnih tvari.
The article of manufacture of embodiment 61, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system. 
Predmet proizvodnje prema patentnom zahtjevu 19, gdje je spomenuta posuda komponenta parenteralnog, subkutanog, - intramuskularnog, = intravenoznog, = intraartikularnog, = intrabronhijalnog, = intraabdominalnog, intrakapsularnog, intrahrskavičavog, intrakavitalnog, intracelularnog, intracerebelarnog, intracerebroventrikularnog, intrakoličnog, intracervikalnog, intragastričnog, intrahepatičkog, intramiokardialnog, intraostealnog, intrakarličnog, intraperikardialnog, intraperitonalnog, intrapleuralnog, intraprostatičnog, intrapulmonalnog, intrarektalnog, intrarenalnog, intraretinalnog, intraspinalnog, intrasinovijalnog, intratorakalnog, intrauterinog, intravezikalnog, intralezionalnog, u bolusu, vaginalnog, rektalnog, bukalnog, sublingvalnog, intranazalnog, ili transdermalnog uređaja za davanje, ili sistema.
The polypeptide of any one of claims 1-2, wherein at least one of the soluble TNF family cytokine domains, particularly at least one of the soluble TNF family cytokine domains (iii) and (v) is a soluble CD95L domain with an N-terminal sequence which starts between amino acid Arg144 to Val146 of human CD95L, and wherein Arg144 and/or Lys145 may be replaced by a neutral amino acid, e.g. by Ser or Gly. 
Polipeptid prema bilo kojem od zahtjeva 1-2 pri kojem je najmanje jedna od topljivih citokinskih domena iz TNF obitelji, naročito najmanje jedna topljiva citokinska domena TNF obitelji (iii) i (v), topljiva TRAIL domena s N-terminalnim slijedom koji počinje između amino kiseline Gln120 1 Val122 od humane TRAIL i pri čemu Arg121 može biti zamijenjena neutralnom aminokiselinom, primjerice Ser ili Gly.
Table 2, above, identifies the compounds TPI 287, TPI 285 and TPI 251, which were found to exhibit excellent inhibition of cell growth against MDR sensitive cancer cell lines. 
Tabela 2, gore, identificira spojeve TPI 287, TPI 2851 TPI 251, za koje je ustanovljeno da pokazuju odlično sprečavanje rasta stanica u odnosu na MDR osjetljive stanične linije karcinoma.
is selected from the group consisting of -heterocyclylR12a, arylR12a, and heteroarylR12a, wherein the heteroaryl is pyridine; wheren R12a is selected from the group consisting of H and halide. 
Spoj prema zahtjevu 1, naznačen time da R' i R* su H i R? je odabran iz skupine koja sadrži -karbociklilR'", - heterociklilR!", -arilR'", i -heteroarilR!".
The pharmaceutical composition according to any one of claims 7-9, wherein the pharmaceutical composition comprises 0.5mg to 1000mg of crystalline 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 7-9, naznačen time da navedeni farmaceutski pripravak sadrži od 0.5 mg do 1000 mg kristalnog 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida.
The use of a compound of any one of embodiments 1 to 11 or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of neurodegenerative disorders in a mammal. 
Tvar iz patentnog zahtjeva 1 ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline za uporabu u liječenju neurodegenerativnih poremećaja u sisavaca.
The movable floating moorage according to claim 12, wherein said spacing secondary pontoons are disposed in mutual correspondence in each pair of adjacent floating booms of the set of parallel floating booms, and the spacing secondary pontoons which are disposed in mutual correspondence between the main pontoons of said pair of adjacent floating booms, are adapted to bear on one another in the second direction for maintaining the respective main pontoons of said adjacent floating booms at said predetermined minimum distance from one another when the actuating system brings together said adjacent floating booms. 
Pokretno plutajuće sidrište prema zahtjevu 12, naznačeno time što su navedeni sekundarni pontoni za održavanje razmaka (7) postavljeni međusobno usklađeno za svaki par susjednih plutajućih brodobrana (5) iz skupa paralelnih plutajućih brodobrana, a sekundarni pontoni za održavanje razmaka koji su smješteni međusobno usklađeno između glavnih pontona (6) iz navedenog para susjednih plutajućih brodobrana, su prilagođeni tako da nose jedan drugoga u drugom smjeru radi održavanja odgovarajućih glavnih pontona navedenih susjednih plutajućih brodobrana na navedenoj unaprijed određenoj minimalnoj međusobnoj udaljenosti kada sustav za aktiviranje spaja navedene susjedne plutajuće brodobrane (5).
a bispecific antibody, wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 12, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 170, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 171. 
26, a treći polipeptid 1 četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 31; 1 nos HR P20180421 T1 (u) bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 12, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO:
a binder comprising an aqueous solution of lithium doped potassium silicate, the binder characterized by an absence of chromium; and an aluminum or aluminum alloy powder incorporated into the binder, wherein the aluminum or the aluminum alloy powder and the binder are contained as a one-part composition, the aluminum or the aluminum alloy powder and the binder contained in a predetermined weight ratio; 
vezivo koje sadrži vodenu otopinu kalijevog silikata obogaćenu litijem, vezivo je karakterizirano odsustvom kroma; i aluminij ili prah aluminijeve slitine ugrađen u vezivo, pri čemu su aluminij ili prah aluminijeve slitine i vezivo sadržani kao jednodijelni sastav, aluminij ili prah aluminijeve slitine i vezivo sadržani su u predodređenom masenom udjelu;
The box as presented according to the invention, features trouble-free construction, while fulfilling three crucial functions: accommodate cigarettes, matches to make use of the cigarettes, and a lighter. 
Kutija kako je prezentirana prema izumu, jednostavne je konstrukcije, a ispunjava tri bitne funkcije: da sadrži cigarete, šibice potrebne za konzumiranje cigareta i upaljač.
The monoclonal antibody or use of any preceding claim, wherein said monoclonal antibody is selected from the group consisting of: 
PTA-5543. Monoklonalno antitijelo prema zahtjevu 1, gdje je navedeno antitijelo monoklonalno antitijelo odabrano iz grupe koja se sastoji od:
The combined organic phases were washed with brine, dried over sodium sulfate and concentrated under reduced pressure, to give (7a,17aB)-17a-ethyl-3-methoxy-7-methyl-D-homoestra-2,5(10)dien-17a-ol. 
Pomiješane organske faze ispere se slanom vodom, osuši preko natrijevog sulfata, te koncentrira pod sniženim tlakom kako bi se dobilo (74,17aB)-17a-etil-3-metoksi-7- metil-D-homoestra-2,5(10)dien-17a-ol.
The dihydrotetrabenazine compounds are typically administered in the form of pharmaceutical compositions. 
Spojevi dihidrotetrabenazina se obično primjenjuju u obliku farmaceutskih pripravaka,
a variable light chain comprising amino acid sequences that are at least 95% identical to the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 3, and a variable heavy chain comprising amino acid sequences that are at least 95% identical to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 5. 
VLhB-B13 sadrži aminokiselinsku sekvencu od SEQ ID NO: 1, VLh8D4-8 sadrži aminokiselinsku sekvencu od SEQ ID NO: 3, VHhB-B13 sadrži aminokiselinsku sekvencu od SEQ ID NO: 2, i VHh8D4-8 sadrži aminokiselinsku sekvencu od SEQ ID NO: 5.
the ratio of cylinder volumes from bottom dead center (BDC) to top dead center (TDC) for either one of the expansion cylinder and compression cylinder being 40 to 1 or greater; and 
Motor (100) iz bilo kojeg prethodnog patentnog zahtjeva, naznačen time što je omjer volumena cilindra od DMT do GMT za ekspanzijski (104) cilindar ili za kompresijski (106) cilindar približno 40 prema 1 ili veći.
An ass's milk-derived food composition, characterized in that it comprises at least: 20-50 g of proteins, 0.1-25 g of lipids, 3.0-20 g of carbohydrates, 1.4-1.6 g of calcium, and 0.9-1.1 of phosphorous for 100 g of the composition. 
HR P20191604 T1 PATENTNI ZAHTJEVI Prehrambeni pripravak dobiven od magarećeg mlijeka, naznačen time što sadrži najmanje: 20-50 g proteina, 0.125 g lipida, 3.0-20 g ugljikohidrata, 1.4-1.6 g kalcija i 0.9-1.1 g fosfora na 100 g pripravka.
Method of heating/bending/forming and heating/toasting barrels, casks, vats or the like according to claim 18, comprising the steps of: 
Postupak grijanja/savijanja/oblikovanja i grijanja/prženja bačava, buradi, badnjeva i slično u skladu s patentnim zahtjevom 17, naznačen time što se sastoji u koracima:
A compound of formula (I): wherein 
Spoj formule (I): u kojem
the variable light chain comprises the variable light chain framework sequence from IGKV4-1 and the CDRs from the VL chain of murine antibody HP1/2, wherein CDR1 comprises the sequence KASQSVTNDVA, CDR2 comprises the sequence YASNRYT and CDR3 comprises the sequence QQDYSSPYT, wherein: 
(b) varijabilni slabi lanac obuhvaća okvirnu sekvencu varijabilnog slabog lanca od IGKV4-1 i CDR-ove od VL-lanca mišjeg protutijela HP1/2, gdje CDR1 obuhvaća sekvencu KASQSVTNDVA, CDR2 obuhvaća sekvencu YASNRYT 1 CDR3 obuhvaća sekvencu QQDYSSPYT, pri čemu su:
The non-crystalline nature of the matrix may also contribute to the long term stability of the water content of lozenges of the invention. 
Ne-kristalna priroda matriksa također može doprinijeti dugotrajnoj stabilnosti količine vode u tableti prema izumu.
Evaluation of biological activity of the compounds 
Broj objave europskog patenta:
Consequently, in a preferred embodiment, after the sensitization with the anti L1 antibody or binding molecule of the invention, the patient is further treated with said chemotherapeutic drug or with said radiotherapy. 
Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 5 ili 6, naznačena time što se nakon sensibiliziranja vežućom molekulom pacijent dodatno liječi. navedenim kemoterapijskim lijekom ili radioterapijom.
The process of claim 1, wherein the high-purity gadobutrol has a purity of greater than 99.7% as determined by high performance liquid chromatography (HPLC). The process of claim 9, wherein the high-purity gadobutrol is a polymorph I monohydrate polymorph of gadobutrol. The process of claim 9, wherein the high-purity gadobutrol has less than 0.01% free Gd3+, less than 0.03% free butrol (N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane) ligand, and less than 0.06% of poly(1-hydroxymethyl-2,3-dihydroxypropyl) cyclen byproducts. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što dobiveni Gadobutrol ima čistoću (prema HPLC) veću od 99,7% koji sadrži manje od 0,01% slobodnih iona gadolinija (III), koji sadrži zaostali sadržaj otapala etanola od manje od 200 ppm i sadrži udio liganda butrola (= N-(1-hidroksimetil-2,3-dihidroksipropil)-1,4,7-triskarboksimetil-1,4,7,10-tetraazaciklododekan) manji od 0,03%.
The serum half-life curves of IL-2 in humans following intravenous bolus administration or infusion can be described as bi-exponential. 
Krivulje polu-života seruma IL-2 kod ljudi koje slijede intravenoznom davanju u bolusu ili infuziji mogu se opisati kao bi-eksponencijalne.
A formulation comprising an aqueous carrier having a pH of 5.5 to 8.0 and a polypeptide comprising one or more single variable domains at a concentration of 1 mg/mL to 200 mg/mL, said formulation being formulated for administration to a human subject and said formulation further comprising a buffer at a concentration of 10mM to 100mM selected from histidine pH 6.0-6.5, wherein said formulation has an inorganic salt concentration of 150 mM or lower and wherein the polypeptide is selected from one of SEQ ID NO's: 1 to 6. 
Formulacija koja sadrži vodeni nosač koji ima pH od 5.5 do 8.0 i polipeptid koji sadrži jednu ili više pojedinačnih varijabilnih domena u koncentraciji od 1 mg/mL do 200 mg/mL, navedena formulacija formulirana je za davanje ljudskom subjektu i navedena formulacija nadalje sadrži histidinski pufer u koncentraciji od 10 mM do 100 mM, pH 6.0-6.5; pri čemu navedena formulacija ima koncentraciju anorganske soli od 150 mM ili nižu, pri čemu je polipeptid odabran od jedne od SEQ ID NO: 1 do 6 i pri čemu pH formulacije iznosi između 6.2 i 7.5.
A container according to any one of the claims 2 to 4, characterized in that the peripheral flange (14) of the lid (4) is adapted to be flush with the outside of a cylindrical wall (2) of the container (1) in the closed position of the lid on the container. 
Spremnik prema bilo kojem od prethodnih zahtjeva, naznačen time što je periferna izbočina (14) poklopca (4) prilagođena da bude ispražnjena vanjskim prostorom izvan stijenke (2) spremnika (1) u zatvorenom položaju poklopca na spremniku.
Evaluation of the antioxidant effect of MAAs 
Datum objave europske prijave patenta:
High solids aqueous suspension of mineral material(s) obtained by the process according to any one of claims 1 to 18, wherein the final solids content of the aqueous suspension obtained after step d) is from 83 to 85 wt%. 
Vodena suspenzija sa visokim udjelom krutih mineralnih materijala dobivena postupkom prema bilo kojem od zahtjeva 1 do 18, naznačena time da je konačni udio krutih tvari u vodenoj suspenziji dobiven nakon koraka d) od 83 do 85 % tež..
The method of claim 1, wherein the meats, plants, or plant parts are selected from the group consisting of corn, wheat, cotton, rice, soybean, and canola. 
Spoj prema patentnom zahtjevu 1, naznačeno time što je spoj formule (B) i odabrano je iz grupe koja se sastoji od i njihovih kombinacija.
A compound of formula (I) as claimed in claim 1 wherein R6 is hydroxy or C1-6 alkyl optionally substituted by piperidinyl, piperazinyl, morpholinyl, homomorpholinyl or homopiperazinyl. 
Spoj formule (I) prema zahtjevima 1 do 3, naznačen time da je R* hidroksi ili C,4 alkil opcionalno supstituiran piperidinilom, piperazinilom, morfolinilom, homomorfolinilom ili homopiperazinilom.
Topical preparations typically contain a suspending agent and optionally, an antifoaming agent. 
Lokalni pripravci tipično sadrže sredstvo za suspendiranje te opcionalno, sredstvo protiv pjenjenja.
7 g, where the outside front wall 8 is made of cardboard, whereat the cut-out 20 is covered with silver foil. 
7g, gdje je vanjski prednji zid 8 napravljen od kartona, dok je otvor 20 prekriven srebrnom folijom.
substituted at 3-position or 4-position on the benzene ring of the matrix; wherein one end of atom N is connected with the matrix; 
HK supstituiran na poziciji 3 ili 4 na benzenskom prstenu matrice; pri čemu je jedan kraj atoma N povezan sa matricom; n n
The average survival rates for each group of recipient animals are summarized in Table 5 and in Figure 12. 
Prosječno preživljenje za svaku grupu životinja primatelja prikazano je u Tablici 5 i na slici 12.
300 mg, was dissolved in 2 mL 95:5 trifluoroacetic acid(TFA):dichloromethane with 1 drop water, and stirred at 45° C. overnight, and purified by preparative HPLC to give L-Y-glutamyl-S-[(4-biphenylyl)methyl)-L-cysteinyl-D-phenylglycine. 
Amino-zaštićeni sulfidni spoj, približno 300 mg, otopljen je u 2 ml 95:5 triflor octene kiseline (TFA): diklor metan sa 1 kapi vode, i miješan preko noći kod 45 "C, te pročišćen preparativnom HPCL da se dobije L-y-glutamil-S-[(4-bifenil)metil]-1-cisteinil-D-fenilglicin.
1654.58 g of venlafaxine hydrochloride were added to the resulting solution and the suspension was homogenised in an appropriate mixer unit a substantially homogeneous suspension was obtained. 
U dobivenu otopinu doda se 1654,58 g venlafaksin- hidroklorida, a suspenziju homogenizira u odgovarajućoj jedinici za miješanje do postizanja uglavnom homogene suspenzije.
polyethylene (PE), polyethylene teraphthalate (PET) and/or polyethylene naphthalate PEN)); polycarbonate; PVC; and/or polypropylene. 
polietilen (PE), polietilen tereftalat (PET) i/ili polietilen naftalat (PEN)); polikarbonata; PVC-a; i/ili polipropilena.
Example 6: Evaluation of the acyclovir saliva concentration 
Datum objave europske prijave patenta:
correlating the presence or absence of the immunological complex with the presence or absence of amyloid protein in the sample; and 
(d) koreliranju prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog proteina u uzorku; i
The oil according to claims 19 or 20 wherein said fatty acids comprise: C16:0 in concentrations of from 7% to 18% by weight, preferably from 10% to 15% by weight; C16:1 in concentrations of from 0% to 2%, preferably from 0.01% to 0.15% by weight; C18:0 in concentrations of from 0.5% to 3.5%, preferably from 1.5% to 3%; C18:1 in concentrations of from 25% to 37%, preferably from 28% to 35%; C18:2 in concentrations of from 44% to 56%, preferably from 47% to 52%; C18:3 (omega 3) in concentrations of from 0.8% to 1.8%; C18:4 in concentrations of from 0% to 0.05%, preferably from 0.005% to 0.02%; C20:0 in concentrations of from 0% to 1%, preferably from 0.3% to 0.8%; C20:1 in concentrations of from 0% to 0.3%, preferably from 0.04% to 0.2%; C22:0 in concentrations of from 0.05% to 0.3%, preferably from 0.08% to 0.2%; C24:0 in concentrations of from 0.05% to 0.4%, preferably from 0.08% to 0-3%. 
Ulje prema zahtjevu 19 ili 20, naznačeno time, da spomenute masne kiseline obuhvaćaju sljedeće: C16:0 u koncentracijama od 7 do 18 masenih %, poželjno od 10 do 15 masenih %; C16:1 u koncentracijama od 0 do 2 masenih %, poželjno od 0,01 do 0,15 masenih %; C18:0 u koncentracijama od 0,5 do 3,5 %, poželjno od 1,5 do 3 %; C18:1 u koncentracijama od 25 do 37 %, poželjno od 28 do 35 %; C18:2 u koncentracijama od 44 do 56 %, poželjno od 47 do 52 %; C18:3 (omega 3) u koncentracijama od 0,8 do 1,8 %; C18:4 u koncentracijama od 0 do 0,05 %, poželjno od 0,005 do 0,02 %; C20:0 u koncentracijama od 0 do 1 %, poželjno od 0,3 do 0,8 %; C20:1 u HR P20121075 T1 koncentracijama od 0 do 0,3 %, poželjno od 0,04 do 0,2 %; C22:0 u koncentracijama od 0,05 do 0,3 %, poželjno od 0,08 do 0,2 %; C24:0 u koncentracijama od 0,05 do 0,4 %, poželjno od 0,08 do 0,3 %;
A safety glove (2) according to claim 6 or 7, wherein said attachment (1) is made of glass fiber. 
Zaštitna rukavica (2) u skladu s patentnim zahtjevom 6 ili 7, naznačena time što je navedeni dodatak (1) načinjen od staklenih vlakana.